TrialX is a New York City-based health informatics company that has been pioneering in the clinical research space since its establishment in 2008. The company's offering is defined by its slogan, "The patient connection," which encapsulates its mission to empower clinical research not only on earth but also in space missions. One of TrialX's key solutions is its Enterprise Patient Recruitment platform, which has proven instrumental in aiding thousands of patients in finding relevant trials and seamlessly connecting them with research teams. An integral feature recently introduced is the Diversity, Equity and Inclusion (DEI) toolkit, which ensures broader representation and inclusivity in patient recruitment workflows. This platform has positioned itself as a central system for patient recruitment operations at major pharmaceutical sponsors, large academic research centers, and patient advocacy groups, offering a comprehensive suite of tools including a clinical trials finder, study website builder, pre-screeners, referral tracking, volunteer registry, and real-time analytics. Additionally, TrialX’s Remote Data Collection platform facilitates the management of hybrid/virtual global clinical trials. With features like eConsent, Pre-screeners, eCOA/ePRO, Cognitive Tasks, Virtual Visits, Push/SMS Reminders, Wearable Integrations, and an analytics dashboard, it provides a fully scalable end-to-end solution for clinical trial teams to manage sites and patients. The company also engages in raising awareness for clinical trials through its platform CureTalks, bringing together patients, patient advocates, and researchers to discuss and highlight the importance of clinical research. With its pioneering approach and innovative solutions, TrialX is carving a unique position in the health informatics sector, with the potential to attract significant interest from venture capitalists who recognize the value in advancing the reach and impact of clinical research and patient recruitment.
There is no investment information
No recent news or press coverage available for TrialX.